Menu Search
Equities

Vertex Pharmaceuticals Inc

VRTX:NSQ

Vertex Pharmaceuticals Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)447.47
  • Today's Change-3.77 / -0.83%
  • Shares traded515.88k
  • 1 Year change+26.12%
  • Beta0.3661
Data delayed at least 15 minutes, as of Nov 21 2024 17:28 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy9
Outperform12
Hold12
Sell1
Strong Sell1

Share price forecast in USD

The 30 analysts offering 12 month price targets for Vertex Pharmaceuticals Incorporated have a median target of 530.00, with a high estimate of 602.00 and a low estimate of 325.00. The median estimate represents a 17.46% increase from the last price of 451.23.
High33.4%602.00
Med17.5%530.00
Low-28.0%325.00

Earnings history & estimates in USD

On Nov 04, 2024, Vertex Pharmaceuticals Incorporated reported 3rd quarter 2024 earnings of 4.38 per share. This result exceeded the 4.14 consensus of the 22 analysts covering the company and exceeded last year's 3rd quarter results by 7.35%.
The next earnings announcement is expected on Feb 03, 2025.
Average growth rate+8.14%
Vertex Pharmaceuticals Incorporated reported annual 2023 earnings of 15.23 per share on Feb 05, 2024.
Average growth rate+34.11%
More ▼

Revenue history & estimates in USD

Vertex Pharmaceuticals Incorporated had 3rd quarter 2024 revenues of 2.77bn. This bettered the 2.72bn consensus of the 26 analysts covering the company. This was 16.72% above the prior year's 3rd quarter results.
Average growth rate+2.84%
Vertex Pharmaceuticals Incorporated had revenues for the full year 2023 of 9.87bn. This was 10.51% above the prior year's results.
Average growth rate+26.34%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.